Therapies

Astellas Bets On Gene Therapy With $3B Audentes Acquisition Offer

8 days ago   |   By Xconomy

Japanese drug giant Astellas Pharma announced late Monday it has agreed to buy Audentes Therapeutics, which is developing gene therapies for rare neuromuscular diseases. It's an all-cash deal worth $3 billion, with the Astellas offer of $60 per share representing a 110 percent premium to Audentes' share price of $28.61 apiece at market close Monday. The agreement is the latest big bet by a major pharmaceutical company on gene therapy, which aims to provide long-lasting, if not permanent, disease treatments. San Francisco-based Audentes' lead drug candidate, AT132, is a clinical-stage...
Read more ...

 

Astellas inks $3B Audentes buyout to expand in gene therapy

Astellas inks $3B Audentes buyout to expand in gene therapy

9 days ago   |   By Fierce Biotech

Astellas Pharma is set to buy Audentes Therapeutics for $3 billion. The deal will enable Astellas to set up a new genetic regulation unit spearheaded by a neuromuscular disease gene therapy that is set to be submitted for approval next year.
Read more ...

 


Search by Tags

   Therapies      Pharmaceutical      Pharma      Therapeutics      Drugs      Drug      Pharmaceuticals      Clinical      Gene      Genes      Gene Therapy      National      National blog main      National top stories      San Francisco blog main      San Francisco top stories      Acquisition      Antitrust      Astellas Pharma      Audentes      Big Pharma      Biotech      Buyout      Clinical trials      Deals      Drug Pricing      FDA      Joseph Schwartz      Life Sciences      M&A      Mergers      Neuromuscular disease      Orbimed      Rare disease      Regulatory review      Roche      Spark      Spark Therapeutics      Startup      SVB Leerink      Genetics  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

How Thermo Fisher Scientific Streamlined Inspection Management With AuditUtopia®

How Thermo Fisher Scientific Streamlined Inspection Management With AuditUtopia®

Case Study Overview In highly regulated industries, you can count on the fact that your company will be inspected a time or two by regulatory agencies and/or your clients. Most... Read more ...

Cover Picture: Biotechnology Journal 12/2019

Cover Picture: Biotechnology Journal 12/2019

Microbial poly‐3‐hydroxybutyrate has been produced via microbial fermentation and safely used as feed additives for sea based large yellow croakers and sensitive land based... Read more ...

A Peek into the Battery Technology Pipeline

A Peek into the Battery Technology Pipeline

Berkeley Lab battery researcher Gerbrand Ceder Lithium ion is probably the most advanced technology available for the packs of rechargeable batteries you'll buy this holiday... Read more ...

Long-Read Sequencing Could Improve the Sensitivity and Precision of 16S...

Long-Read Sequencing Could Improve the Sensitivity and Precision of 16S Sequencing Says Jackson Lab Study

It's time to revisit the way scientists are using 16S rRNA gene sequencing to study microorganisms, according to a team of Jackson Laboratory researchers. Popular targets for... Read more ...

Iterum's Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink

Iterum's Antibiotic for Super Bugs Falls Short in Phase 3, Shares Sink

Iterum Therapeutics' bid to bring patients a new antibiotic that's safer than currently available drugs has fallen short of the main efficacy goal of a late-stage clinical... Read more ...

Flagship's Cellarity Aims to Advance Cell Behavior-Based Therapeutics

Flagship's Cellarity Aims to Advance Cell Behavior-Based Therapeutics

The latest startup to emerge from Flagship Pioneering aims to change drug discovery by starting the process with a clear understanding of cell behavior. Cellarity-like many... Read more ...

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

KalVista Pharma Eye Drug Partnered With Merck Flunks Phase 2 Test

A KalVista Pharmaceuticals eye drug at the center of a research collaboration with Merck has failed a mid-stage clinical trial. KalVista developed its drug, KVD001, to treat... Read more ...

Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

Zentalis Steps Out With $147M Raised to Develop “Tried and True” Small Molecules

Zentalis Pharmaceuticals is banking on small molecules for cancer-leaving the “cool technologies” aside for a “tried and true” approach, says the CEO, who wants to let the... Read more ...

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer

The Scripps Research Institute and AbbVie have agreed to broaden an existing drug discovery agreement focused on cancer cell therapies to now encompass treatments for other... Read more ...

From Hawaii to PECASE award: tips of success from a female bioinformatician

Read more ...